Data gathered: October 21
Alternative Data for Organon & Co.
About Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
| Price | $9.02 |
| Target Price | Sign up |
| Volume | 3,910,000 |
| Market Cap | $2.41B |
| Year Range | $8.02 - $16.06 |
| Dividend Yield | 9.17% |
| PE Ratio | 3.45 |
| Analyst Rating | 43% buy |
| Industry | Drug Manufacturers |
In the news
 |
Is Prolonged Revenue and EPS Decline Altering the Investment Case for Organon (OGN)?October 17 - Yahoo |
|
Organon (OGN) Stock Declines While Market Improves: Some Information for InvestorsOctober 17 - Yahoo |
|
Organon (OGN) Dips More Than Broader Market: What You Should KnowOctober 16 - Yahoo |
|
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals StocksOctober 8 - Yahoo |
|
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowOctober 7 - Yahoo |
|
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You TradeOctober 6 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 1.59B | 720M | 874M | 145M | 449M | 1.000 |
| Q1 '25 | 1.51B | 672M | 841M | 87M | 325M | 1.020 |
| Q4 '24 | 1.59B | 696M | 896M | 109M | 341M | 0.900 |
| Q3 '24 | 1.58B | 659M | 923M | 359M | 402M | 0.870 |
| Q2 '24 | 1.61B | 668M | 939M | 195M | 432M | 1.120 |
Insider Transactions View All
| COX CARRIE SMITH filed to buy 12,469 shares at $8.1. May 15 '25 |
| Falcione Aaron filed to buy 62,974 shares at $8.8. May 7 '25 |
| Karp Daniel filed to buy 46,669 shares at $8.2. May 7 '25 |
| Weaver Kirke filed to buy 52,489 shares at $9.2. May 7 '25 |
| Ali Kevin filed to buy 282,731 shares at $8.8. May 6 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$191.88 0.9% | 63 |
 |
Eli Lilly and CompanyLLY |
$799.57 1.2% | 59 |
 |
PfizerPFE |
$24.85 0.6% | 57 |
 |
AstrazenecaAZN |
$83.22 0.8% | 63 |
 |
AbbVieABBV |
$231.39 0.3% | 60 |
Read more about Organon & Co. (OGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Organon & Co.?
The Market Cap of Organon & Co. is $2.41B.
What is Organon & Co.'s PE Ratio?
As of today, Organon & Co.'s PE (Price to Earnings) ratio is 3.45.
What is the current stock price of Organon & Co.?
Currently, the price of one share of Organon & Co. stock is $9.02.
How can I analyze the OGN stock price chart for investment decisions?
The OGN stock price chart above provides a comprehensive visual representation of Organon & Co.'s stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Organon & Co. shares. Our platform offers an up-to-date OGN stock price chart, along with technical data analysis and alternative data insights.
Does OGN offer dividends to its shareholders?
Yes, Organon & Co. (OGN) offers dividends to its shareholders, with a dividend yield of 9.17%. This dividend yield represents Organon & Co.'s commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Organon & Co. in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Organon & Co.?
Some of the similar stocks of Organon & Co. are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.
